v3.25.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Revenues $ 212 $ 93 $ 355 $ 175
Cost of revenues 14 16 25 21
Gross profit 198 77 330 154
Operating expenses        
Selling, general and administrative 2,881 2,713 6,366 5,369
Research and development 155 81 258 118
Acquired in-process research and development 1,848 0 1,967 0
Total operating expenses 4,884 2,794 8,591 5,487
Operating loss (4,686) (2,717) (8,261) (5,333)
Other expenses, net        
Interest income 3 7 21 40
Change in fair value of royalties payable due to related parties (1,667) (1,504) (2,830) (1,590)
Change in fair value of trading debt securities 10 0 10 0
Other expenses, net (1) (1) (1) (4)
Total other expenses, net (1,722) (1,503) (2,916) (1,562)
Loss from operations before income taxes (6,408) (4,220) (11,177) (6,895)
Income tax benefit (950) 0 (1,674) 0
Net loss (5,458) (4,220) (9,503) (6,895)
Less: Net loss attributable to non-controlling interest (349) 0 (349) 0
Net loss attributable to Catheter Precision, Inc. $ (5,109) $ (4,220) $ (9,154) $ (6,895)
Net loss per share attributable to Catheter Precision, Inc., basic and diluted (in dollars per share) $ (0.38) $ (5.57) $ (0.74) $ (9.19)
Weighted-average common shares used in computing net loss per share, basic and diluted (in shares) 13,336,088 757,340 12,341,614 750,130
Product [Member]        
Revenues $ 212 $ 93 $ 355 $ 175
Service [Member]        
Other expenses, net        
Interest expense $ (67) $ (5) $ (116) $ (8)